Orthocell (ASX:OCC) secured approval to market and sell its Remplir nerve repair collagen wrap from the Singaporean Health Science Authority, according to a Tuesday filing with the Australian bourse.

This is the first approval for the device outside of Australia and New Zealand in a country considered to be the gateway for the ASEAN market, the filing said.

The device is expected to be distributed to the Singaporean market by the first quarter of next year, as per the filing.

The company's shares rose past 5% in recent Tuesday trade and earlier hit their highest level since May 2021.

Price (AUD): $0.51, Change: $+0.03, Percent Change: +5.21%